The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes

Yao, Hsien-Tsung; Chang, Yu-Hao; Lan, Shih-Jung; Chen, Chiung‐Tong; Hsu, Ju Wei; Yeh, Teng‐Kuang

doi:10.1016/j.lfs.2006.08.016

Cited by 79 publications

(71 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent studies identified PUFAs as inhibitors of rodent and human CYP3A activities. 36,37 The induction of Cyp3a11 transcript, also reported by others, 38 may thus be secondary to the reduction in enzymatic activity and restore a constitutive CYP3A hepatic activity. We also observed an overexpression of CAR in PPAR␣ Ϫ/Ϫ livers (Fig.…”

Section: Discussionmentioning

confidence: 63%

Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study

Martin¹,

Guillou²,

Lasserre³

et al. 2007

Hepatology

113

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 63%

Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study

Martin¹,

Guillou²,

Lasserre³

et al. 2007

Hepatology

113

View full text Add to dashboard Cite

“…Specific combinations of chemotherapy and antioxidants (e.g., vitamin E and cisplatin) have been studied, and evidence suggests beneficial effects, including reducing adverse effects for some with no reduced efficacy of the chemotherapy involved. 15,16 Similarly, several studies document the effectiveness of fish-oil use by patients with cancer to reduce adverse effects of cancer treatment; evidence of risk associated with the combination comes only from in vitro studies. 9,17,18 However, this is a controversial area, and there is a clear theoretical potential for reduced efficacy of therapies; clinical care decisions for both patients and providers are difficult without further information.…”

Section: Discussionmentioning

confidence: 99%

Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer

Andersen

Sweet

Lowe

et al. 2013

The Journal of Alternative and Complementary Medicine

View full text Add to dashboard Cite

Objective: Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together. Methods: A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment. Results: A total of 200 women reported having chemotherapy to treat their ovarian cancer. Of those, 79 (40%) reported using 1 or more CAM supplements that could be cause for concern when taken with 1 or more of the chemotherapy medications they were receiving. Many patients took multiple supplements of potential concern. Of these women, 42% (n = 33) consulted with a conventional provider and 24% (n = 19) consulted with a CAM provider about the contraindicated supplements they used. Conclusion: Although it is not clear that any of these contraindicated combinations of CAM and conventional therapy actually caused adverse outcomes, increased toxicities, or reduced the effectiveness of primary therapies, all these effects are possible given the substances being used in combination. Research is needed to understand the real risk associated with CAM and conventional polypharmacy. If risks associated with CAM use prove substantial, then improved systems to assure that all women get advice regarding supplement use during ovarian cancer treatment will be needed.

show abstract

“…A population-based study (52) found that Caucasians but not African Americans with IIe/Val (CYP1A1*2C) genotype were at a lower risk of developing lung cancer than those with lle/lle (*1/*1) genotype, after adjusting for age at diagnosis, sex, years of smoking and family history of cancer. A recent study (53) (105)Val. The study included 504 women aged 18 to 74, diagnosed with non-small cell lung cancer (NSCLC) and 527 controls.…”

Section: Cyp1a1mentioning

confidence: 98%

“…It metabolises about 15 % of drugs in current use, some of which are of substantial clinical importance such as angiotensin-2 antagonists, nonsteroidal antiinfl ammatory drugs (NSAIDs), oral antidiabetics, antiepileptics, oral anticoagulants, psychotropic drugs, and alkylating anticancer prodrugs (Table 4) (103,104). In addition, CYP2C9 metabolises endogenous substrates arachidonic and linolenic acid (105). CYP2C9 also mediates 3-hydroxylation of B[a]P and metabolic activation of several PAH-diols to active metabolites at much slower rates than those by CYP1 enzymes (106).…”

Section: Cyp2c9mentioning

confidence: 99%

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

Božina¹,

Bradamante

Lovrić

2009

Archives of Industrial Hygiene and Toxicology

165

111

View full text Add to dashboard Cite

The polymorphic P450 (CYP) enzyme superfamily is the most important system involved in the biotransformation of many endogenous and exogenous substances including drugs, toxins, and carcinogens. Genotyping for CYP polymorphisms provides important genetic information that help to understand the effects of xenobiotics on human body. For drug metabolism, the most important polymorphisms are those of the genes coding for CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5, which can result in therapeutic failure or severe adverse reactions. Genes coding for CYP1A1, CYP1A2, CYP1B1, and CYP2E1 are among the most responsible for the biotransformation of chemicals, especially for the metabolic activation of pre-carcinogens. There is evidence of association between gene polymorphism and cancer susceptibility. Pathways of carcinogen metabolism are complex, and are mediated by activities of multiple genes, while single genes have a limited impact on cancer risk. Multigenic approach in addition to environmental determinants in large sample studies is crucial for a reliable evaluation of any moderate gene effect. This article brings a review of current knowledge on the relations between the polymorphisms of some CYPs and drug activity/toxicity and cancer risk.

show abstract

The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes

Cited by 79 publications

References 21 publications

Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study

Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study

Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

Contact Info

Product

Resources

About